Adjuvant systemic therapy along with screening has been key to the observed
improvements in disease-free and overall survival (DFS/OS) in breast cancer. Improvements …

Women with primary invasive breast cancer receive both local and systemic treatment.
Surgery and radiation therapy are local treatments given to reduce the risk of recurrent …

Background Doxorubicin is one of the most commonly prescribed and time-tested anticancer
drugs. Although being considered as a first line drug in different types of cancers, the two …

Purpose Limited data are available on long-term cardiac safety of adjuvant anthracycline
chemotherapy in breast cancer patients over age 65 years. We evaluated rates and …

The decision to receive chemotherapy or chemohormonal therapy involves careful
consideration of both the potential benefits and possible risks of therapy. There are …

Despite the known cardiotoxic effects of doxorubicin and other anthracyclines, no evidence-
based guidelines exist for the surveillance and prevention of chemotherapy-induced …

Breast cancer is the most common malignant tumor affecting women. Adjuvant systemic
therapies have been shown to have a significant impact on reducing the risk for breast …

Anthracyclines remain among the most widely prescribed and effective anticancer agents.
Unfortunately, life-threatening cardiotoxicity continues to compromise their usefulness …

Survivors of adult cancer face lifetime health risks that are dependent on their cancer, cancer
treatment exposures, comorbid health conditions, genetic predispositions, and lifestyle …

Purpose To compare the incidence and distribution of coronary artery disease after left-
sided versus right-sided irradiation in patients treated with breast conservation for early …